Theratechnologies (NASDAQ:THTX), facing continuity concerns, has revised its fiscal revenue target to $82-$85 million following a mid-July adjustment. The revision comes as the firm reported a reduced third-quarter loss of $746,000 on Tuesday. The company's three-month revenue stands at $20.9 million.
In an effort to stabilize its financial position, Theratechnologies is seeking lender backing, a liquidity breach waiver, and stringent expense management under its amended 2022 credit agreement. The company has indicated that an equity issue could be on the horizon if these plans do not materialize.
Adding to its strategic initiatives, Theratechnologies has submitted a concentrated "F8" tesamorelin formulation for review. This new formulation could potentially reduce the administration volume for HIV-related lipodystrophy treatment, offering a more efficient approach to managing this condition. The submission of the "F8" tesamorelin formulation represents the company's ongoing commitment to innovation and patient care in the face of its current financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.